SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort

Journal of Urology

Volumn 196, Issue 5, 2016, Pages 1436-1444

  Johnson, Michael H ^a   Ross, Ashley E ^a   Alshalalfa, Mohammed ^b   Erho, Nicholas ^b   Yousefi, Kasra ^b   Glavaris, Stephanie ^a   Fedor, Helen ^a   Han, Misop ^a   Faraj, Sheila F ^a   Bezerra, Stephania M ^a   Netto, George ^a   Partin, Alan W ^a   Trock, Bruce J ^a   Davicioni, Elai ^b   Schaeffer, Edward M ^c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b GenomeDx Biosciences Inc   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

genomics; neoplasm metastasis; prognosis; prostatic neoplasms; transcriptome

Indexed keywords

ERG ETS FUSION PROTEIN; HYBRID PROTEIN; PROTEIN; PROTEIN SPINK1; UNCLASSIFIED DRUG; APROTININ; SPINK1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL OUTCOME; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE; RISK FACTOR; CLASSIFICATION; COHORT ANALYSIS; DISEASE EXACERBATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; RETROSPECTIVE STUDY; TIME FACTOR;

ADULT; AGED; COHORT STUDIES; DISEASE PROGRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRYPSIN INHIBITOR, KAZAL PANCREATIC;

EID: 84992348938     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.05.092     Document Type: Article

References (23)

1. 1 SEER Stat Fact Sheet: Prostate Cancer. Available at http://seer.cancer.gov/statfacts/html/prost.html. Accessed August 1, 2015.
2. 2 Cooperberg, M.R., Hilton, J.F., Carroll, P.R., The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer, 117, 2011, 5039.
3. 3 Erho, N., Crisan, A., Vergara, I.A., et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One, 8, 2013, e66855.
4. 4 Klein, E.A., Cooperberg, M.R., Magi-Galluzzi, C., et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol, 66, 2014, 550.
5. 5 Penney, K.L., Sinnott, J.A., Fall, K., et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol, 29, 2011, 2391.
6. 6 Cuzick, J., Stone, S., Fisher, G., et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer, 113, 2015, 382.
7. 7 Den, R.B., Yousefi, K., Trabulsi, E.J., et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol, 33, 2015, 944.
8. 8 Karnes, R.J., Bergstralh, E.J., Davicioni, E., et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol, 190, 2013, 2047.
9. 9 Tomlins, S.A., Alshalalfa, M., Davicioni, E., et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol, 68, 2015, 555.
10. 10 Tomlins, S.A., Rhodes, D.R., Yu, J., et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell, 13, 2008, 519.
11. 11 Rubin, M.A., ETS rearrangements in prostate cancer. Asian J Androl, 14, 2012, 393.
12. 12 Arora, R., Koch, M.O., Eble, J.N., et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer, 100, 2004, 2362.
13. 13 Ross, A.E., Johnson, M.H., Yousefi, K., et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol, 69, 2016, 157.
14. 14 Piccolo, S.R., Sun, Y., Campbell, J.D., et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics, 100, 2012, 337.
15. 15 Kumar, A., Coleman, I., Morrissey, C., et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med, 22, 2016, 369.
16. 16 Svensson, M.A., LaFargue, C.J., MacDonald, T.Y., et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest, 91, 2011, 404.
17. 17 Ateeq, B., Tomlins, S.A., Laxman, B., et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med, 3, 2011, 72ra17.
18. 18 Flavin, R., Pettersson, A., Hendrickson, W.K., et al. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res, 20, 2014, 4904.
19. 19 Blattner, M., Lee, D.J., O'Reilly, C., et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia, 16, 2014, 14.
20. 20 Berg, K.D., Vainer, B., Thomsen, F.B., et al. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol, 66, 2014, 851.
21. 21 Galletti, G., Matov, A., Beltran, H., et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun, 5, 2014, 5548.
22. 22 Palanisamy, N., Tsodikov, A., Yan, W., et al. Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial. Urol Oncol, 33, 2015, 108.
23. 23 Pound, C.R., Partin, A.W., Eisenberger, M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281, 1999, 1591.